336 related articles for article (PubMed ID: 30510618)
1. Therapeutic Use of mTOR Inhibitors in Renal Diseases: Advances, Drawbacks, and Challenges.
Viana SD; Reis F; Alves R
Oxid Med Cell Longev; 2018; 2018():3693625. PubMed ID: 30510618
[TBL] [Abstract][Full Text] [Related]
2. mTOR Inhibition and Kidney Diseases.
Ma MKM; Yung S; Chan TM
Transplantation; 2018 Feb; 102(2S Suppl 1):S32-S40. PubMed ID: 29369972
[TBL] [Abstract][Full Text] [Related]
3. Role of mTOR Inhibitors in Kidney Disease.
Kajiwara M; Masuda S
Int J Mol Sci; 2016 Jun; 17(6):. PubMed ID: 27338360
[TBL] [Abstract][Full Text] [Related]
4. Roles of mTOR complexes in the kidney: implications for renal disease and transplantation.
Fantus D; Rogers NM; Grahammer F; Huber TB; Thomson AW
Nat Rev Nephrol; 2016 Oct; 12(10):587-609. PubMed ID: 27477490
[TBL] [Abstract][Full Text] [Related]
5. Distinct signaling mechanisms of mTORC1 and mTORC2 in glioblastoma multiforme: a tale of two complexes.
Jhanwar-Uniyal M; Gillick JL; Neil J; Tobias M; Thwing ZE; Murali R
Adv Biol Regul; 2015 Jan; 57():64-74. PubMed ID: 25442674
[TBL] [Abstract][Full Text] [Related]
6. Mammalian target of rapamycin and the kidney. I. The signaling pathway.
Lieberthal W; Levine JS
Am J Physiol Renal Physiol; 2012 Jul; 303(1):F1-10. PubMed ID: 22419691
[TBL] [Abstract][Full Text] [Related]
7. mTOR in renal cell cancer: modulator of tumor biology and therapeutic target.
Wysocki PJ
Expert Rev Mol Diagn; 2009 Apr; 9(3):231-41. PubMed ID: 19379082
[TBL] [Abstract][Full Text] [Related]
8. mTOR kinase inhibitors as a treatment strategy in hematological malignancies.
Grzybowska-Izydorczyk O; Smolewski P
Future Med Chem; 2012 Mar; 4(4):487-504. PubMed ID: 22416776
[TBL] [Abstract][Full Text] [Related]
9. Cellular and molecular effects of the mTOR inhibitor everolimus.
Saran U; Foti M; Dufour JF
Clin Sci (Lond); 2015 Nov; 129(10):895-914. PubMed ID: 26330617
[TBL] [Abstract][Full Text] [Related]
10. Dissecting the role of mTOR: lessons from mTOR inhibitors.
Dowling RJ; Topisirovic I; Fonseca BD; Sonenberg N
Biochim Biophys Acta; 2010 Mar; 1804(3):433-9. PubMed ID: 20005306
[TBL] [Abstract][Full Text] [Related]
11. New inhibitors of the mammalian target of rapamycin signaling pathway for cancer.
Albert S; Serova M; Dreyer C; Sablin MP; Faivre S; Raymond E
Expert Opin Investig Drugs; 2010 Aug; 19(8):919-30. PubMed ID: 20569080
[TBL] [Abstract][Full Text] [Related]
12. mTOR and rapamycin in the kidney: signaling and therapeutic implications beyond immunosuppression.
Huber TB; Walz G; Kuehn EW
Kidney Int; 2011 Mar; 79(5):502-11. PubMed ID: 21085109
[TBL] [Abstract][Full Text] [Related]
13. Advances in understanding the mechanisms of evasive and innate resistance to mTOR inhibition in cancer cells.
Chiarini F; Evangelisti C; Lattanzi G; McCubrey JA; Martelli AM
Biochim Biophys Acta Mol Cell Res; 2019 Aug; 1866(8):1322-1337. PubMed ID: 30928610
[TBL] [Abstract][Full Text] [Related]
14. Systemic and nonrenal adverse effects occurring in renal transplant patients treated with mTOR inhibitors.
Zaza G; Tomei P; Ria P; Granata S; Boschiero L; Lupo A
Clin Dev Immunol; 2013; 2013():403280. PubMed ID: 24151517
[TBL] [Abstract][Full Text] [Related]
15. Impact of mammalian target of rapamycin inhibition on autosomal-dominant polycystic kidney disease.
Wüthrich RP; Kistler AD; Serra AL
Transplant Proc; 2010 Nov; 42(9 Suppl):S44-6. PubMed ID: 21095452
[TBL] [Abstract][Full Text] [Related]
16. Current and future directions in mammalian target of rapamycin inhibitors development.
Fasolo A; Sessa C
Expert Opin Investig Drugs; 2011 Mar; 20(3):381-94. PubMed ID: 21299441
[TBL] [Abstract][Full Text] [Related]
17. [Extra-renal adverse effects of mTOR inhibitors: know them to optimize their use in renal transplantation].
Caletti C; Granata S; Tomei P; Lupo A; Zaza G
G Ital Nefrol; 2014; 31(4):. PubMed ID: 25098457
[TBL] [Abstract][Full Text] [Related]
18. Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenib.
Serova M; de Gramont A; Tijeras-Raballand A; Dos Santos C; Riveiro ME; Slimane K; Faivre S; Raymond E
Cancer Chemother Pharmacol; 2013 May; 71(5):1297-307. PubMed ID: 23479136
[TBL] [Abstract][Full Text] [Related]
19. New inhibitors of the PI3K-Akt-mTOR pathway: insights into mTOR signaling from a new generation of Tor Kinase Domain Inhibitors (TORKinibs).
Feldman ME; Shokat KM
Curr Top Microbiol Immunol; 2010; 347():241-62. PubMed ID: 20549474
[TBL] [Abstract][Full Text] [Related]
20. The preclinical assessment of XL388, a mTOR kinase inhibitor, as a promising anti-renal cell carcinoma agent.
Xiong Z; Zang Y; Zhong S; Zou L; Wu Y; Liu S; Fang Z; Shen Z; Ding Q; Chen S
Oncotarget; 2017 May; 8(18):30151-30161. PubMed ID: 28404914
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
